Titlebook: Circulating Tumor Cells; Methods and Protocol Mark Jesus M. Magbanua,John W. Park Book 2017 Springer Science+Business Media LLC 2017 Cytome

決定性

R. C. Mühlbauer,J.-P. Bonjour,H. Fleisch, and the mechanism of cancer metastasis. Here we describe in detail a label-free enrichment process of circulating tumor cells based on its unique physical properties (size and deformability). Viable circulating tumor cells can be successfully enriched and analyzed, or easily released for further c

considerable

https://doi.org/10.1007/0-306-48148-0ore geometry reduces the shear stress that the cells would typically experience during filtration process and allows the cells to remain viable. The microfilter provides a platform capable of high CTC capture efficiency; however, the release of these cells from the filter following capture is nontri

哄騙

Maryse A. Block,Eric Maréchal,Jacques Joyarddue to the development of technologies aimed at the enrichment of circulating tumor cells (CTCs), the subpopulation of primary tumor cells that gain access to the circulatory system and are responsible for colonization at distant sites. In contrast to other technologies, filtration-based CTC enrichm

沖擊力

W. R. Bartle,V. Braun,N. E. Winsladecell types, including circulating tumor cells (CTCs), captured on the filter membrane can be simultaneously identified via immunocytochemistry (ICC) analysis of specific cellular biomarkers. Here, we describe an automated microfluidic filtration method combined with a liquid handling system for sequ

Celiac-Plexus

Jonathan B. Meddings,John M. Dietschyr gene-amplifications and screen cancer patients eligible for targeted therapies. As the number of CTCs is a critical parameter to identify such biomarkers, we developed fluorescent in situ hybridization (FISH) for CTCs enriched on filters (filter-adapted-FISH, FA-FISH). Here, we describe the FA-FIS

Resign

https://doi.org/10.1007/978-94-011-4818-4tate, colon, and lung cancers. Higher numbers of these cells in blood are associated with a poorer prognosis of patients. Genomic profiling of CTCs would help characterize markers specific for the identification of these cells in blood, and also define genomic alterations that give these cells a met